Brief: Shenzhen Hepalink Pharmaceutical Says Oncovent Biomedical Agreed To Grant Exclusive Rights To Orient Europharma
27/03/2023 14:28
March 27 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group 002399.SZ :
* ONCOVENT BIOMEDICAL AGREED TO GRANT EXCLUSIVE RIGHTS TO
ORIENT
EUROPHARMA
* IN DEAL, TO GRANT PRE-EMPTIVE RIGHT OF EXCLUSIVE SALE,
MARKETING, DISTRIBUTION RIGHTS OF OREGOVOMAB IN HK AND MACAU
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA